Published in Respir Res on December 07, 2004
Angiogenesis in interstitial lung diseases: a pathogenetic hallmark or a bystander? Respir Res (2006) 0.96
Serum biomarkers in interstitial lung diseases. Respir Res (2005) 0.85
Serum biomarkers in acute respiratory distress syndrome an ailing prognosticator. Respir Res (2005) 0.85
Meta-analysis of genetic programs between idiopathic pulmonary fibrosis and sarcoidosis. PLoS One (2013) 0.84
Integrating genomic and clinical medicine: searching for susceptibility genes in complex lung diseases. Transl Res (2007) 0.82
Microarray analysis of differential gene expression profile in peripheral blood cells of patients with human essential hypertension. Int J Med Sci (2011) 0.80
Microarray profiling of lymphocytes in internal diseases with an altered immune response: potential and methodology. Mediators Inflamm (2005) 0.79
Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science (1995) 88.48
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
The transcriptional program of sporulation in budding yeast. Science (1998) 37.23
Genetics of gene expression surveyed in maize, mouse and man. Nature (2003) 22.17
Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell (2002) 17.32
DNA arrays for analysis of gene expression. Methods Enzymol (1999) 12.50
Expression profiling using cDNA microarrays. Nat Genet (1999) 11.58
Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med (1999) 8.96
Delineating developmental and metabolic pathways in vivo by expression profiling using the RIKEN set of 18,816 full-length enriched mouse cDNA arrays. Proc Natl Acad Sci U S A (2001) 6.07
Protein microarrays and proteomics. Nat Genet (2002) 4.17
Loss of integrin alpha(v)beta6-mediated TGF-beta activation causes Mmp12-dependent emphysema. Nature (2003) 4.02
Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci U S A (2002) 4.00
Stereotyped and specific gene expression programs in human innate immune responses to bacteria. Proc Natl Acad Sci U S A (2002) 3.85
Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis. Proc Natl Acad Sci U S A (2000) 3.47
Neutrophils as early immunologic effectors in hemorrhage- or endotoxemia-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol (2000) 2.58
Global expression profiling of fibroblast responses to transforming growth factor-beta1 reveals the induction of inhibitor of differentiation-1 and provides evidence of smooth muscle cell phenotypic switching. Am J Pathol (2003) 2.14
Biological markers of acute lung injury: prognostic and pathogenetic significance. Am J Respir Crit Care Med (1997) 2.10
FIZZ1 stimulation of myofibroblast differentiation. Am J Pathol (2004) 2.06
Variability of antioxidant-related gene expression in the airway epithelium of cigarette smokers. Am J Respir Cell Mol Biol (2003) 2.05
In vivo antioxidant treatment suppresses nuclear factor-kappa B activation and neutrophilic lung inflammation. J Immunol (1996) 1.96
High-density microarrays for gene expression analysis. Cytometry (2001) 1.80
Surfactant and the adult respiratory distress syndrome. Am Rev Respir Dis (1993) 1.79
Microarray analysis of eosinophils reveals a number of candidate survival and apoptosis genes. Am J Respir Cell Mol Biol (2001) 1.78
Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med (2002) 1.76
Granulocyte apoptosis and the control of inflammation. Philos Trans R Soc Lond B Biol Sci (1994) 1.75
The alliance of genes and environment in asthma and allergy. Nature (1999) 1.70
Gene expression profiling in inflammatory airway disease associated with elevated adenosine. Am J Physiol Lung Cell Mol Physiol (2002) 1.55
Practical approaches to analyzing results of microarray experiments. Am J Respir Cell Mol Biol (2002) 1.55
Interleukin-13 induces dramatically different transcriptional programs in three human airway cell types. Am J Respir Cell Mol Biol (2001) 1.48
Smoking and chronic obstructive pulmonary disease. Clin Chest Med (2000) 1.43
Gene expression profiling of the early pulmonary response to hyperoxia in mice. Am J Respir Cell Mol Biol (2003) 1.41
Sensitivity issues in DNA array-based expression measurements and performance of nylon microarrays for small samples. Hum Mol Genet (1999) 1.39
Molecular signatures of sepsis: multiorgan gene expression profiles of systemic inflammation. Am J Pathol (2001) 1.33
Functional classes of bronchial mucosa genes that are differentially expressed in asthma. BMC Genomics (2004) 1.32
HOX genes in human lung: altered expression in primary pulmonary hypertension and emphysema. Am J Pathol (2001) 1.29
Transcriptional response of human mast cells stimulated via the Fc(epsilon)RI and identification of mast cells as a source of IL-11. BMC Immunol (2002) 1.28
Microarray profile of differentially expressed genes in a monkey model of allergic asthma. Genome Biol (2002) 1.20
Identification of genes differentially over-expressed in lung squamous cell carcinoma using combination of cDNA subtraction and microarray analysis. Oncogene (2000) 1.14
Methods and approaches in the analysis of gene expression data. J Immunol Methods (2001) 1.13
Differential gene expression in the initiation and progression of nickel-induced acute lung injury. Am J Respir Cell Mol Biol (2000) 1.10
Molecular monitoring of bleomycin-induced pulmonary fibrosis by cDNA microarray-based gene expression profiling. Biochem Biophys Res Commun (2001) 1.09
DNA microarrays in medical practice. BMJ (2001) 1.05
Chemokines in bronchiolar epithelium in the development of chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol (2004) 1.05
Lymphoid tissue and emphysema in the lungs of transgenic mice inducibly expressing tumor necrosis factor-alpha. Am J Respir Cell Mol Biol (2003) 1.04
COPD in perspective. Chest (2002) 1.01
Association between IL-1beta/TNF-alpha-induced glucocorticoid-sensitive changes in multiple gene expression and altered responsiveness in airway smooth muscle. Am J Respir Cell Mol Biol (2001) 1.01
International consensus statement on idiopathic pulmonary fibrosis. Eur Respir J (2001) 0.96
Role of NF-kappaB in endotoxemia-induced alterations of lung neutrophil apoptosis. J Immunol (2001) 0.96
Feature extraction and signal processing for nylon DNA microarrays. BMC Genomics (2004) 0.95
Genetics of allergy and asthma. Ann Allergy Asthma Immunol (1999) 0.93
cDNA microarray analysis of rat alveolar epithelial cells following exposure to organic extract of diesel exhaust particles. Toxicol Appl Pharmacol (2004) 0.91
Array-based diagnostic gene-expression score for atopy and asthma. J Allergy Clin Immunol (2002) 0.90
Changes in bronchoalveolar lavage fluid proteins in sarcoidosis: a proteomics approach. Eur Respir J (2003) 0.89
Atopy and asthma genes--where do we stand? Allergy (2000) 0.89
Gene expression profiling: good housekeeping and a clean message. Thorax (2002) 0.88
Apoptosis signals in atopy and asthma measured with cDNA arrays. Clin Exp Immunol (2001) 0.87
Genetics of asthma: a review. Chest (1997) 0.86
The use of microarrays in medicine. Isr Med Assoc J (2001) 0.86
Differences between basophils and mast cells: failure to detect Charcot-Leyden crystal protein (lysophospholipase) and eosinophil granule major basic protein in human mast cells. J Immunol (1986) 0.85
CCR7 (EBI1) receptor down-regulation in asthma: differential gene expression in human CD4+ T lymphocytes. QJM (1999) 0.82
Pulmonary inflammation and edema induced by phospholipase A2: global gene analysis and effects on aquaporins and Na+/K+-ATPase. J Biol Chem (2003) 0.82
The genetics of gene expression and gene mapping. Trends Biotechnol (2003) 0.82
Roger S. Mitchell lecture. Uses of expression microarrays in studies of pulmonary fibrosis, asthma, acute lung injury, and emphysema. Chest (2002) 0.80
Gene expression profiles of human small airway epithelial cells treated with low doses of 14- and 16-membered macrolides. Biochem Biophys Res Commun (2001) 0.79
Functional genomics in sarcoidosis--reduced or increased apoptosis? Swiss Med Wkly (2001) 0.78
Surfactant and acute lung injury. Proc Assoc Am Physicians (1999) 0.78
Gene expression analysis in interstitial lung edema induced by saline infusion. Biochim Biophys Acta (2003) 0.77
Genomic microarrays: arraying order in biological chaos? Am J Respir Cell Mol Biol (2001) 0.76
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med (2013) 6.82
Pleural effusions in hematologic malignancies. Chest (2004) 3.14
Inhibition and role of let-7d in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2010) 3.02
Comparative expression profiling in pulmonary fibrosis suggests a role of hypoxia-inducible factor-1alpha in disease pathogenesis. Am J Respir Crit Care Med (2007) 1.67
Global impairment of CD4+CD25+FOXP3+ regulatory T cells in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2009) 1.51
Prevention of nosocomial maxillary sinusitis in the ICU: the effects of topically applied alpha-adrenergic agonists and corticosteroids. Intensive Care Med (2006) 1.48
Interferons and their application in the diseases of the lung. Chest (2003) 1.45
Expression of apoptotic and antiapoptotic markers in epithelial cells in idiopathic pulmonary fibrosis. Chest (2005) 1.39
A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. J Transl Med (2013) 1.21
Long-term effect of continuous positive airway pressure therapy on inflammation markers of patients with obstructive sleep apnea syndrome. Sleep (2009) 1.21
Video-assisted thoracoscopic surgery for thoracic empyema: primarily, or after fibrinolytic therapy failure? Am J Surg (2004) 1.17
Fat embolism syndrome: clinical examination is still the preferable diagnostic method. Chest (2003) 1.15
Effect of continuous positive airway pressure treatment on serum cardiovascular risk factors in patients with obstructive sleep apnea-hypopnea syndrome. Chest (2007) 1.14
Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Cell Mol Biol (2012) 1.13
The effect of obesity on pulmonary lung function of school aged children in Greece. Pediatr Pulmonol (2009) 1.10
Warfarin in idiopathic pulmonary fibrosis: friend or foe, is it a matter of genes and heparin? Am J Respir Crit Care Med (2013) 1.09
The predictive role of serum and bronchoalveolar lavage cytokines and adhesion molecules for acute respiratory distress syndrome development and outcome. Respir Res (2002) 1.08
Obstructive sleep apnea aggravates glycemic control across the continuum of glucose homeostasis. Am J Respir Crit Care Med (2010) 1.08
COPD and IPF: it's all about regulation and balance. Thorax (2014) 1.07
Stem cell therapy for idiopathic pulmonary fibrosis: a protocol proposal. J Transl Med (2011) 1.07
Evaluation of health-related quality-of-life and dyspnea scales in patients with idiopathic pulmonary fibrosis. Correlation with pulmonary function tests. Eur J Intern Med (2005) 1.06
A prospective study of the diagnostic utility of sputum Gram stain in pneumonia. J Infect (2009) 1.05
Acute fibrinous and organising pneumonia: a case report and review of the literature. J Med Case Rep (2009) 1.05
The pathogenesis of pulmonary fibrosis: a moving target. Eur Respir J (2012) 1.03
Different angiogenic activity in pulmonary sarcoidosis and idiopathic pulmonary fibrosis. Chest (2006) 1.02
Smoking acutely increases plasma ghrelin concentrations. Clin Chem (2006) 1.01
γ-H2AX expression detected by immunohistochemistry correlates with prognosis in early operable non-small cell lung cancer. Onco Targets Ther (2012) 1.00
Inflammatory markers in middle-aged obese subjects: does obstructive sleep apnea syndrome play a role? Mediators Inflamm (2010) 0.98
Angiogenesis in interstitial lung diseases: a pathogenetic hallmark or a bystander? Respir Res (2006) 0.96
Prognostic value of serum tumor markers in patients with lung cancer. Respiration (2002) 0.96
Increased incidence of autoimmune markers in patients with combined pulmonary fibrosis and emphysema. BMC Pulm Med (2013) 0.96
Community acquired bacterial pneumonia. Expert Opin Pharmacother (2010) 0.95
Induced sputum CD8+ T-lymphocyte subpopulations in chronic obstructive pulmonary disease. Respir Med (2004) 0.95
Pleural effusions in critically ill patients. Respiration (2008) 0.95
Involvement of lymphatic metastatic spread in non-small cell lung cancer accordingly to the primary cancer location. Lung Cancer (2004) 0.94
The relationships among hydrogen peroxide in expired breath condensate, airway inflammation, and asthma severity. Chest (2002) 0.94
Intrapleural streptokinase for pleural infection. BMJ (2006) 0.94
HbA1c is associated with severity of obstructive sleep apnea hypopnea syndrome in nondiabetic men. Vasc Health Risk Manag (2009) 0.93
Upregulation of Th1 cytokine profile (IL-12, IL-18) in bronchoalveolar lavage fluid in patients with pulmonary sarcoidosis. J Interferon Cytokine Res (2006) 0.92
Pathogenetic pathways and novel pharmacotherapeutic targets in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther (2006) 0.92
The clinical significance of serum and bronchoalveolar lavage inflammatory cytokines in patients at risk for Acute Respiratory Distress Syndrome. BMC Pulm Med (2004) 0.92
Lung cancer and interstitial lung diseases: a systematic review. Pulm Med (2012) 0.92
Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis. Pulm Med (2012) 0.92
Combined pulmonary fibrosis and emphysema. Expert Rev Respir Med (2013) 0.91
Exhaled H(2)O(2) in steady-state bronchiectasis: relationship with cellular composition in induced sputum, spirometry, and extent and severity of disease. Chest (2002) 0.91
Stem cell therapy in pulmonary fibrosis. Curr Opin Pulm Med (2011) 0.91
Markers of glycemic control and insulin resistance in non-diabetic patients with Obstructive Sleep Apnea Hypopnea Syndrome: does adherence to CPAP treatment improve glycemic control? Sleep Med (2009) 0.91
Pulmonary hypertension in idiopathic pulmonary fibrosis: a review. Respiration (2011) 0.90
Comorbidities and chronic obstructive pulmonary disease: is there a place for lung fibrosis? Am J Respir Crit Care Med (2013) 0.90
Sleepiness as a marker of glucose deregulation in obstructive sleep apnea. Sleep Breath (2011) 0.89
Formoterol in the management of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2008) 0.89
Biomarkers in the Evaluation and Management of Idiopathic Pulmonary Fibrosis. Curr Top Med Chem (2016) 0.89
The cost of COPD exacerbations: a university hospital--based study in Greece. Respir Med (2011) 0.89
Recombinant tissue plasminogen activator in the treatment of pleural infections in adults. Respir Med (2008) 0.88
Clinical features of lung cancer in patients with connective tissue diseases: a 10-year hospital based study. Respir Med (2008) 0.88
Continuous positive airway pressure treatment in patients with sleep apnoea: does it really improve glucose metabolism? Curr Diabetes Rev (2010) 0.88
Lower respiratory tract infections caused by Haemophilus influenzae: clinical features and predictors of outcome. Med Sci Monit (2009) 0.87
Sleep apnea syndrome and diastolic blood pressure elevation during exercise. Respiration (2004) 0.87
Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study. Can Respir J (2002) 0.87
Phase 1 trial of lipoplatin and gemcitabine as a second-line chemotherapy in patients with nonsmall cell lung carcinoma. Cancer (2008) 0.87
Expression of hypoxia-inducible factor (HIF)-1a-vascular endothelial growth factor (VEGF)-inhibitory growth factor (ING)-4- axis in sarcoidosis patients. BMC Res Notes (2012) 0.87
Stem cell treatment for chronic lung diseases. Respiration (2013) 0.87
Stem cell therapy in chronic obstructive pulmonary disease. Seeking the Prometheus effect. Curr Drug Targets (2013) 0.86
Sleep-disordered breathing and quality of life of railway drivers in Greece. Chest (2008) 0.86
Effects of antifibrotic agents on TGF-beta1, CTGF and IFN-gamma expression in patients with idiopathic pulmonary fibrosis. Respir Med (2007) 0.86
Prevalence and clinical characteristics of obesity hypoventilation syndrome among individuals reporting sleep-related breathing symptoms in northern Greece. Sleep Breath (2010) 0.86
Current evidence for the management of paediatric parapneumonic effusions. Curr Med Res Opin (2012) 0.86
Combined pulmonary fibrosis and emphysema associated with microscopic polyangiitis. Eur Respir J (2012) 0.85
Increased expression of epidermal growth factor receptor (EGF-R) in patients with different forms of lung fibrosis. Biomed Res Int (2013) 0.85
Serum biomarkers in acute respiratory distress syndrome an ailing prognosticator. Respir Res (2005) 0.85
Down-regulation of the inhibitor of growth family member 4 (ING4) in different forms of pulmonary fibrosis. Respir Res (2009) 0.85
Serum biomarkers in interstitial lung diseases. Respir Res (2005) 0.85
Diagnostic value of interleukin-1alpha, interleukin-6, and tumor necrosis factor in pleural effusions. Chest (2002) 0.84
Expression of prolyl-hydroxylases PHD-1, 2 and 3 and of the asparagine hydroxylase FIH in non-small cell lung cancer relates to an activated HIF pathway. Cancer Lett (2008) 0.84
Th1/Th2 cytokine pattern in bronchoalveolar lavage fluid and induced sputum in pulmonary sarcoidosis. BMC Pulm Med (2005) 0.84
Current pharmacological treatment of pulmonary arterial hypertension. Curr Clin Pharmacol (2008) 0.83
A trial of intrapleural streptokinase. N Engl J Med (2005) 0.83
Autophagy and Bcl-2/BNIP3 death regulatory pathway in non-small cell lung carcinomas. APMIS (2012) 0.82
Determinants of continuous positive airway pressure compliance in a group of Greek patients with obstructive sleep apnea. Eur J Intern Med (2009) 0.82
Autoimmunity and chronic obstructive pulmonary disease: thinking beyond cigarette smoke. Am J Respir Crit Care Med (2012) 0.82
8-Isoprostane, a marker of oxidative stress, is increased in the expired breath condensate of patients with pulmonary sarcoidosis. Chest (2004) 0.82
Decreased apoptotic rate of alveolar macrophages of patients with idiopathic pulmonary fibrosis. Pulm Med (2012) 0.82
Quality of life in patients with active sarcoidosis in Greece. Eur J Intern Med (2006) 0.82
Predictors of obstructive sleep apnea in males with metabolic syndrome. Vasc Health Risk Manag (2010) 0.82
Steep barriers to overcome for successful application of stem cell treatment in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2013) 0.81
E-cadherin expression on fine-needle aspiration biopsies in primary lung adenocarcinomas is related to tumor differentiation and invasion. Anticancer Res (2003) 0.81
Continuous positive airways pressure treatment in a patient with sleep apnea-hypopnea syndrome and coexisting bipolar disorder. Psychopharmacol Bull (2008) 0.81
Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC). Anticancer Res (2008) 0.80
Low-dose clarithromycin therapy modulates Th17 response in non-cystic fibrosis bronchiectasis patients. Lung (2014) 0.80
Mechanisms of pleural involvement in orphan diseases. Respiration (2012) 0.80
Serologic evaluation in idiopathic interstitial pneumonias. Curr Opin Pulm Med (2012) 0.80
Plasma visfatin levels in severe obstructive sleep apnea-hypopnea syndrome. Sleep Breath (2009) 0.80
Simultaneous EGFR and VEGF alterations in non-small cell lung carcinoma based on tissue microarrays. Cancer Inform (2007) 0.80
Reduction in cotton dust concentration does not totally eliminate respiratory health hazards: the Greek study. Toxicol Ind Health (2010) 0.79
Triplet chemotherapy with docetaxel, gemcitabine and liposomal doxorubicin, supported with subcutaneous amifostine and hemopoietic growth factors, in advanced non-small cell lung cancer. Anticancer Res (2005) 0.79
Comparative analysis of induced sputum and bronchoalveolar lavage fluid (BALF) profile in asbestos exposed workers. J Occup Med Toxicol (2011) 0.79
Bronchiolitis: adopting a unifying definition and a comprehensive etiological classification. Expert Rev Respir Med (2013) 0.79
Intrapleural r-tPA in association with low-molecular heparin may cause massive hemothorax resulting in hypovolemia. Respiration (2010) 0.79
Continuous positive airway pressure treatment: effect on serum lipids in patients with obstructive sleep apnoea. Open Cardiovasc Med J (2011) 0.79